These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 33268125)

  • 21. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
    Noordman BJ; Spaander MCW; Valkema R; Wijnhoven BPL; van Berge Henegouwen MI; Shapiro J; Biermann K; van der Gaast A; van Hillegersberg R; Hulshof MCCM; Krishnadath KK; Lagarde SM; Nieuwenhuijzen GAP; Oostenbrug LE; Siersema PD; Schoon EJ; Sosef MN; Steyerberg EW; van Lanschot JJB;
    Lancet Oncol; 2018 Jul; 19(7):965-974. PubMed ID: 29861116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Impact of Pretreatment PET/CT Nodal Status on Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiation.
    Chen JX; Lu TY; Fang HY; Lin YS; Lee JM
    World J Surg; 2020 Jul; 44(7):2323-2331. PubMed ID: 32296872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
    Chen J; Yin W; Yao H; Gu W
    Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological Significance of Pathologic Complete Lymph Node Regression After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma.
    Hsu PK; Yeh YC; Chien LI; Huang CS; Hsu HS
    Ann Surg Oncol; 2021 Apr; 28(4):2048-2058. PubMed ID: 33216266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Yun JK; Kim Y; Lee GD; Choi S; Kim YH; Kim DK; Park SI; Kim HR
    Cancer Med; 2022 Oct; 11(19):3623-3632. PubMed ID: 35434935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy.
    Li Q; Zhou S; Liu S; Liu S; Yang H; Zhao L; Liu M; Hu Y; Xi M
    Ann Surg Oncol; 2019 Sep; 26(9):2882-2889. PubMed ID: 31037433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    BMC Cancer; 2021 Nov; 21(1):1192. PubMed ID: 34753448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anatomical distribution of residual cancer in patients with oesophageal squamous cell carcinoma who achieved clinically complete response after neoadjuvant chemoradiotherapy.
    Chao YK; Chuang WY; Yeh CJ; Chang HK; Tseng CK
    Eur J Cardiothorac Surg; 2018 Jan; 53(1):201-208. PubMed ID: 28977486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of radiation dose and predicted tumor invasion depth on local recurrence after definitive chemoradiotherapy for stage 0-I esophageal squamous cell carcinoma: a propensity score-weighted, retrospective, observational study.
    Ikawa T; Ishihara R; Matsueda K; Konishi K; Yamamoto S; Morimoto M; Kanayama N; Teshima T
    BMC Cancer; 2022 Mar; 22(1):301. PubMed ID: 35313853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery.
    Wang X; Wang H; Wang H; Huang J; Wang X; Jiang Z; Tan L; Jiang D; Hou Y
    BMC Cancer; 2021 Feb; 21(1):111. PubMed ID: 33535987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
    Anand S; Bhati G; Gurram R; Gnanasekaran S; Kate V; Pottakkat B; Kalayarasan R
    J Gastrointest Cancer; 2021 Jun; 52(2):659-665. PubMed ID: 32607960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SUV
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    World J Surg Oncol; 2021 Apr; 19(1):105. PubMed ID: 33836789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
    Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
    Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
    [No Abstract]   [Full Text] [Related]  

  • 36. Correlation Between Tumor Regression Grade and Clinicopathological Parameters in Patients With Squamous Cell Carcinoma of the Esophagus Who Received Neoadjuvant Chemoradiotherapy.
    Chao YK; Chang CB; Chuang WY; Wen YW; Chang HK; Tseng CK; Yeh CJ; Liu YH
    Medicine (Baltimore); 2015 Aug; 94(34):e1407. PubMed ID: 26313788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
    Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
    Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study.
    Wang H; Zhang X; Zhao X; Song C; Deng W; Shen W
    Front Immunol; 2023; 14():1330928. PubMed ID: 38274807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
    Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
    Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic relevance of serial endoscopic ultrasound after chemoradiation in esophageal cancer.
    Bohle W; Kasper M; Zoller WG
    Dis Esophagus; 2017 Oct; 30(10):1-8. PubMed ID: 28859390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.